Methylmalonic Acidemia (MMA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Methylmalonic acidemia (MMA) is a term used to describe a set of inherited disorders where the body’s ability to process specific proteins and lipids (fats) is impaired. Individuals with MMA cannot properly metabolize a substance called methylmalonyl-coenzyme A, accumulating methylmalonic acid in their bodies. Additionally, methylmalonic acid levels can rise in individuals who lack vitamin B12 for reasons unrelated to genetics. This condition stems from mutations in various genes. It can be categorized into two groups: 1) those with isolated MMA, characterized by elevated methylmalonic acid levels only, and 2) individuals with combined defects who also exhibit heightened homocysteine levels. Mutations in the MMAA, MMAB, and MUT genes are responsible for isolated methylmalonic acidemia, with approximately half of cases involving MUT gene mutations. The MUT gene provides instructions for producing an enzyme called methylmalonyl CoA mutase, crucial in breaking down several amino acids (essential for protein formation), specific lipids, and cholesterol. Mutations in the MUT gene alter the enzyme’s structure or reduce its quantity, leading to inadequate breakdown of these molecules. Consequently, methylmalonyl-CoA and other potentially harmful substances accumulate, causing the symptoms associated with methylmalonic acidemia. Most forms of methylmalonic acidemia follow an autosomal recessive inheritance pattern, meaning both parents of an affected child are carriers of the condition and do not show symptoms. During each pregnancy between two carrier parents, there is a 25% chance that the child will be unaffected and not a carrier, a 50% chance that the child will be unaffected but become a carrier, and a 25 percent chance that the child will be affected by methylmalonic acidemia. Once an at-risk sibling is confirmed as unaffected, their likelihood of being a carrier is 66 percent, and siblings of a carrier parent have a 50 percent chance of being carriers. The clinical manifestations of MMA are diverse and not specific to the disease type or the extent of enzyme deficiency. Primary symptoms of MMA encompass difficulties with feeding, intellectual disability, psychomotor retardation, ataxia (lack of muscle coordination), abnormal muscle tone, seizures, epilepsy, and lethargy. These clinical presentations do not display distinct, overt signs and symptoms but rather underscore the multifaceted nature of this condition, which can also exhibit age-related features. There is no cure for methylmalonic acidemia, and the prognosis varies widely, ranging from a matter of days to several years. The overall mortality rate for isolated MMA is 50 percent, with a median age of death at around 2 years.
• In the United States, the collective incidence of MMA, as determined by newborn screening programs, is approximately 1 in 159,614 births.

Thelansis’s “Methylmalonic Acidemia (MMA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Methylmalonic Acidemia (MMA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Methylmalonic Acidemia (MMA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Methylmalonic Acidemia (MMA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Methylmalonic Acidemia (MMA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Methylmalonic Acidemia (MMA), Methylmalonic Acidemia (MMA) market outlook, Methylmalonic Acidemia (MMA) competitive landscape, Methylmalonic Acidemia (MMA) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)